TSFAX
Price
$16.92
Change
+$0.07 (+0.42%)
Updated
Jul 31 closing price
Net Assets
258.54M
VSCIX
Price
$141.38
Change
-$0.34 (-0.24%)
Updated
Jul 31 closing price
Net Assets
188.57B
Interact to see
Advertisement

TSFAX vs VSCIX

TSFAX vs VSCIX Comparison Chart in %
View a ticker or compare two or three
VS
TSFAX vs. VSCIX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TSFAX is a Buy and VSCIX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSCIX has more cash in the bank: 189B vs. TSFAX (259M). VSCIX pays higher dividends than TSFAX: VSCIX (1.23) vs TSFAX (0.00). TSFAX was incepted earlier than VSCIX: TSFAX (17 years) vs VSCIX (29 years). TSFAX (1.53) is less costly to investors than VSCIX (0.03). VSCIX is a more actively managed with annual turnover of: 17.00 vs. TSFAX (11.00). TSFAX has a lower initial minimum investment than VSCIX: TSFAX (2500) vs VSCIX (5000000). VSCIX annual gain was more profitable for investors over the last year : 22.58 vs. TSFAX (17.50). VSCIX return over 5 years is better than : 35.13 vs. TSFAX (19.49).
TSFAXVSCIXTSFAX / VSCIX
Total Expense Ratio1.250.034,167%
Annual Report Gross Expense Ratio1.530.035,100%
Fund Existence17 years29 years-
Gain YTD12.80014.59188%
Front Load5%N/A-
Min. Initial Investment250050000000%
Min. Initial Investment IRAN/AN/A-
Net Assets259M189B0%
Annual Yield % from dividends0.001.23-
Returns for 1 year17.5022.5877%
Returns for 3 years23.3343.4454%
Returns for 5 years19.4935.1355%
Returns for 10 years1.71156.071%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GSPKX20.050.12
+0.60%
Goldman Sachs US Eq Div and Prem Instl
GSIQX23.62N/A
N/A
Goldman Sachs GQG Ptnrs Intl Opps R
HSIIX29.59-0.08
-0.27%
Carillon Eagle Small Cap Growth I
CCWSX21.56-0.16
-0.74%
Baird Chautauqua International Gr Inv
RYCFX49.56-1.15
-2.27%
Rydex Biotechnology C